Protocol Ledger

NCT04300790 · Phase II · COMPLETED

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

Interventional Phase II clinical trial protocol NCT04300790 sponsored by MedSIR in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-10-23 Enrollment: 69 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04300790
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)69 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04300790
Protocol FieldVerified Registry Value
NCT IdentifierNCT04300790
Consolidated Lead SponsorMedSIR
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment69 participants (ACTUAL)
Registered Start Date2020-10-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04300790
Hospital Research SiteLocationSite Profile
Hospital General Universitario de AlicanteAlicante, SpainOpen Hospital Dossier ->
Hospital Universitari Vall d'HebronBarcelona, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI